.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

AstraZeneca
Daiichi Sankyo
Queensland Health
Julphar
Teva
Accenture
Farmers Insurance
Cantor Fitzgerald
Moodys
McKinsey

Generated: September 24, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Which drugs does patent 6,811,794 protect, and when does it expire?


Patent ► Subscribe protects INTUNIV and is included in one NDA. There has been one Paragraph IV challenge on Intuniv.

Protection for INTUNIV has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

Summary for Patent: ► Subscribe

Title: Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
Abstract:A pharmaceutical composition comprising at least one pharmaceutically active agent that is pH dependent, at least one non-pH dependent sustained release agent, and at least one pH dependent agent that increases the dissolution rate of the at least one pharmaceutically active agent at a pH in excess of 5.5. Such compositions have minimized pH-dependent dissolution profiles or pH-independent dissolution profiles.
Inventor(s): Burnside; Beth A. (Bethesda, MD), Chang; Rong-Kun (Rockville, MD), Guo; Xiaodi (New City, NY)
Assignee: Shire Laboratories, Inc. (Rockville, MD)
Application Number:10/027,349
Patent Claim Types:
see list of patent claims
Composition; Compound; Use; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Shire
INTUNIV
guanfacine hydrochloride
TABLET, EXTENDED RELEASE;ORAL022037-001Sep 2, 2009ABRXYesNo► Subscribe► SubscribeY
Shire
INTUNIV
guanfacine hydrochloride
TABLET, EXTENDED RELEASE;ORAL022037-002Sep 2, 2009ABRXYesNo► Subscribe► SubscribeY
Shire
INTUNIV
guanfacine hydrochloride
TABLET, EXTENDED RELEASE;ORAL022037-003Sep 2, 2009ABRXYesNo► Subscribe► SubscribeY
Shire
INTUNIV
guanfacine hydrochloride
TABLET, EXTENDED RELEASE;ORAL022037-004Sep 2, 2009ABRXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Boehringer Ingelheim
Cerilliant
Julphar
Daiichi Sankyo
Johnson and Johnson
Merck
Moodys
Fish and Richardson
Harvard Business School
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot